APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gastrointestinal Cancer Drugs Market Outlook and Growth Opportunities 2026

Report ID 173994210421 December 2025199 pages

Choose your research edition.

Industry ResearchGastrointestinal Cancer Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Cancer Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Cancer Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Cancer Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Gastrointestinal Cancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gastrointestinal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastrointestinal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastrointestinal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gastrointestinal Cancer Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gastrointestinal Cancer Drugs market include Sanofi, Johnson & Johnson Private, Novartis, Roche, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb Company and Celgene Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gastrointestinal Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastrointestinal Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastrointestinal Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastrointestinal Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Gastrointestinal Cancer Drugs Segment by Company

Sanofi

Johnson & Johnson Private

Novartis

Roche

Eli Lilly and Company

Pfizer

GlaxoSmithKline

Bristol-Myers Squibb Company

Celgene Corporation

Amgen & Amgen Ireland

Gastrointestinal Cancer Drugs Segment by Type

Oncology

Radiology

Others

Gastrointestinal Cancer Drugs Segment by Application

Specialized Cancer Treatment Centers

Clinics

Hospitals

Ambulatory Surgical Centers

Gastrointestinal Cancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gastrointestinal Cancer Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gastrointestinal Cancer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastrointestinal Cancer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Gastrointestinal Cancer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastrointestinal Cancer Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastrointestinal Cancer Drugs industry.

Chapter 3: Detailed analysis of Gastrointestinal Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gastrointestinal Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gastrointestinal Cancer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastrointestinal Cancer Drugs Industry Trends Table 2. Gastrointestinal Cancer Drugs Industry Drivers Table 3. Gastrointestinal Cancer Drugs Industry Opportunities and Challenges Table 4. Gastrointestinal Cancer Drugs Industry Restraints Table 5. Global Gastrointestinal Cancer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastrointestinal Cancer Drugs Revenue Share by Company (2021-2026) Table 7. Global Gastrointestinal Cancer Drugs Sales Volume by Company (g) & (2021-2026) Table 8. Global Gastrointestinal Cancer Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Gastrointestinal Cancer Drugs Average Price (US$/g) of Company (2021-2026) Table 10. Global Gastrointestinal Cancer Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gastrointestinal Cancer Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Gastrointestinal Cancer Drugs Company, Product Type & Application Table 13. Global Gastrointestinal Cancer Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gastrointestinal Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oncology Table 18. Significant Companies of Radiology Table 19. Significant Companies of Others Table 20. Global Gastrointestinal Cancer Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (g) Table 21. Global Gastrointestinal Cancer Drugs Sales Volume by Type (2021-2026) & (g) Table 22. Global Gastrointestinal Cancer Drugs Sales Volume by Type (2027-2032) & (g) Table 23. Global Gastrointestinal Cancer Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Gastrointestinal Cancer Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Gastrointestinal Cancer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gastrointestinal Cancer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Gastrointestinal Cancer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Gastrointestinal Cancer Drugs Sales Value Share by Type (2021-2026) Table 29. Global Gastrointestinal Cancer Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Specialized Cancer Treatment Centers Table 31. Significant Companies of Clinics Table 32. Significant Companies of Hospitals Table 33. Significant Companies of Ambulatory Surgical Centers Table 34. Global Gastrointestinal Cancer Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (g) Table 35. Global Gastrointestinal Cancer Drugs Sales Volume by Application (2021-2026) & (g) Table 36. Global Gastrointestinal Cancer Drugs Sales Volume by Application (2027-2032) & (g) Table 37. Global Gastrointestinal Cancer Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Gastrointestinal Cancer Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Gastrointestinal Cancer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Gastrointestinal Cancer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Gastrointestinal Cancer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Gastrointestinal Cancer Drugs Sales Value Share by Application (2021-2026) Table 43. Global Gastrointestinal Cancer Drugs Sales Value Share by Application (2027-2032) Table 44. Global Gastrointestinal Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (g) Table 45. Global Gastrointestinal Cancer Drugs Sales by Region (2021-2026) & (g) Table 46. Global Gastrointestinal Cancer Drugs Sales Market Share by Region (2021-2026) Table 47. Global Gastrointestinal Cancer Drugs Sales by Region (2027-2032) & (g) Table 48. Global Gastrointestinal Cancer Drugs Sales Market Share by Region (2027-2032) Table 49. Global Gastrointestinal Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Gastrointestinal Cancer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Gastrointestinal Cancer Drugs Sales Value Share by Region (2021-2026) Table 52. Global Gastrointestinal Cancer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Gastrointestinal Cancer Drugs Sales Value Share by Region (2027-2032) Table 54. Global Gastrointestinal Cancer Drugs Market Average Price (US$/g) by Region (2021-2026) Table 55. Global Gastrointestinal Cancer Drugs Market Average Price (US$/g) by Region (2027-2032) Table 56. Global Gastrointestinal Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (g) Table 57. Global Gastrointestinal Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Gastrointestinal Cancer Drugs Sales by Country (2021-2026) & (g) Table 59. Global Gastrointestinal Cancer Drugs Sales Market Share by Country (2021-2026) Table 60. Global Gastrointestinal Cancer Drugs Sales by Country (2027-2032) & (g) Table 61. Global Gastrointestinal Cancer Drugs Sales Market Share by Country (2027-2032) Table 62. Global Gastrointestinal Cancer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Gastrointestinal Cancer Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Gastrointestinal Cancer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Gastrointestinal Cancer Drugs Sales Value Market Share by Country (2027-2032) Table 66. Sanofi Company Information Table 67. Sanofi Business Overview Table 68. Sanofi Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 69. Sanofi Gastrointestinal Cancer Drugs Product Portfolio Table 70. Sanofi Recent Development Table 71. Johnson & Johnson Private Company Information Table 72. Johnson & Johnson Private Business Overview Table 73. Johnson & Johnson Private Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 74. Johnson & Johnson Private Gastrointestinal Cancer Drugs Product Portfolio Table 75. Johnson & Johnson Private Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 79. Novartis Gastrointestinal Cancer Drugs Product Portfolio Table 80. Novartis Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 84. Roche Gastrointestinal Cancer Drugs Product Portfolio Table 85. Roche Recent Development Table 86. Eli Lilly and Company Company Information Table 87. Eli Lilly and Company Business Overview Table 88. Eli Lilly and Company Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 89. Eli Lilly and Company Gastrointestinal Cancer Drugs Product Portfolio Table 90. Eli Lilly and Company Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 94. Pfizer Gastrointestinal Cancer Drugs Product Portfolio Table 95. Pfizer Recent Development Table 96. GlaxoSmithKline Company Information Table 97. GlaxoSmithKline Business Overview Table 98. GlaxoSmithKline Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 99. GlaxoSmithKline Gastrointestinal Cancer Drugs Product Portfolio Table 100. GlaxoSmithKline Recent Development Table 101. Bristol-Myers Squibb Company Company Information Table 102. Bristol-Myers Squibb Company Business Overview Table 103. Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 104. Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Product Portfolio Table 105. Bristol-Myers Squibb Company Recent Development Table 106. Celgene Corporation Company Information Table 107. Celgene Corporation Business Overview Table 108. Celgene Corporation Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 109. Celgene Corporation Gastrointestinal Cancer Drugs Product Portfolio Table 110. Celgene Corporation Recent Development Table 111. Amgen & Amgen Ireland Company Information Table 112. Amgen & Amgen Ireland Business Overview Table 113. Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Sales (g), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 114. Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Product Portfolio Table 115. Amgen & Amgen Ireland Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. Gastrointestinal Cancer Drugs Distributors List Table 119. Gastrointestinal Cancer Drugs Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Gastrointestinal Cancer Drugs Product Image Figure 2. Global Gastrointestinal Cancer Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastrointestinal Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gastrointestinal Cancer Drugs Sales (2021-2032) & (g) Figure 5. Global Gastrointestinal Cancer Drugs Sales Average Price (US$/g) & (2021-2032) Figure 6. Global Gastrointestinal Cancer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oncology Image Figure 10. Radiology Image Figure 11. Others Image Figure 12. Global Gastrointestinal Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (g) Figure 13. Global Gastrointestinal Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Gastrointestinal Cancer Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Gastrointestinal Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gastrointestinal Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Gastrointestinal Cancer Drugs Sales Value Share by Type (2021-2032) Figure 18. Specialized Cancer Treatment Centers Image Figure 19. Clinics Image Figure 20. Hospitals Image Figure 21. Ambulatory Surgical Centers Image Figure 22. Global Gastrointestinal Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (g) Figure 23. Global Gastrointestinal Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Gastrointestinal Cancer Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Gastrointestinal Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Gastrointestinal Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Gastrointestinal Cancer Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Gastrointestinal Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (g) Figure 29. Global Gastrointestinal Cancer Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Gastrointestinal Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Gastrointestinal Cancer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Gastrointestinal Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Gastrointestinal Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Gastrointestinal Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Gastrointestinal Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Gastrointestinal Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Gastrointestinal Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Gastrointestinal Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Gastrointestinal Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Gastrointestinal Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Gastrointestinal Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Gastrointestinal Cancer Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Gastrointestinal Cancer Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Oncology
  • Radiology
  • Others
Applications
  • Specialized Cancer Treatment Centers
  • Clinics
  • Hospitals
  • Ambulatory Surgical Centers
Companies covered
  • Sanofi
  • Johnson & Johnson Private
  • Novartis
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Amgen & Amgen Ireland

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gastrointestinal Cancer Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Gastrointestinal Cancer Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Gastrointestinal Cancer Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gastrointestinal Cancer Drugs Market Dynamics
  1. 2.1 Gastrointestinal Cancer Drugs Industry Trends
  2. 2.2 Gastrointestinal Cancer Drugs Industry Drivers
  3. 2.3 Gastrointestinal Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Gastrointestinal Cancer Drugs Industry Restraints
3 Gastrointestinal Cancer Drugs Market by Company
  1. 3.1 Global Gastrointestinal Cancer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Gastrointestinal Cancer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Gastrointestinal Cancer Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Gastrointestinal Cancer Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Gastrointestinal Cancer Drugs Company Ranking (2024-2026)
  6. 3.6 Global Gastrointestinal Cancer Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Gastrointestinal Cancer Drugs Company Product Type and Application
  8. 3.8 Global Gastrointestinal Cancer Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gastrointestinal Cancer Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gastrointestinal Cancer Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gastrointestinal Cancer Drugs Market by Type
  1. 4.1 Gastrointestinal Cancer Drugs Type Introduction
  2. 4.1.1 Oncology
  3. 4.1.2 Radiology
  4. 4.1.3 Others
  5. 4.2 Global Gastrointestinal Cancer Drugs Sales Volume by Type
  6. 4.2.1 Global Gastrointestinal Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Gastrointestinal Cancer Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Gastrointestinal Cancer Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Gastrointestinal Cancer Drugs Sales Value by Type
  10. 4.3.1 Global Gastrointestinal Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Gastrointestinal Cancer Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Gastrointestinal Cancer Drugs Sales Value Share by Type (2021-2032)
5 Gastrointestinal Cancer Drugs Market by Application
  1. 5.1 Gastrointestinal Cancer Drugs Application Introduction
  2. 5.1.1 Specialized Cancer Treatment Centers
  3. 5.1.2 Clinics
  4. 5.1.3 Hospitals
  5. 5.1.4 Ambulatory Surgical Centers
  6. 5.2 Global Gastrointestinal Cancer Drugs Sales Volume by Application
  7. 5.2.1 Global Gastrointestinal Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Gastrointestinal Cancer Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Gastrointestinal Cancer Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Gastrointestinal Cancer Drugs Sales Value by Application
  11. 5.3.1 Global Gastrointestinal Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Gastrointestinal Cancer Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Gastrointestinal Cancer Drugs Sales Value Share by Application (2021-2032)
6 Gastrointestinal Cancer Drugs Regional Sales and Value Analysis
  1. 6.1 Global Gastrointestinal Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastrointestinal Cancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Gastrointestinal Cancer Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Gastrointestinal Cancer Drugs Sales by Region (2027-2032)
  5. 6.3 Global Gastrointestinal Cancer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gastrointestinal Cancer Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gastrointestinal Cancer Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gastrointestinal Cancer Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Gastrointestinal Cancer Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gastrointestinal Cancer Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Gastrointestinal Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gastrointestinal Cancer Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Gastrointestinal Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gastrointestinal Cancer Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gastrointestinal Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gastrointestinal Cancer Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Gastrointestinal Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gastrointestinal Cancer Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gastrointestinal Cancer Drugs Sales Value Share by Country, 2025 VS 2032
7 Gastrointestinal Cancer Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Gastrointestinal Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastrointestinal Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gastrointestinal Cancer Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Gastrointestinal Cancer Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Gastrointestinal Cancer Drugs Sales by Country (2027-2032)
  6. 7.4 Global Gastrointestinal Cancer Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gastrointestinal Cancer Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gastrointestinal Cancer Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gastrointestinal Cancer Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gastrointestinal Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gastrointestinal Cancer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Gastrointestinal Cancer Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson Private
  8. 8.2.1 Johnson & Johnson Private Company Information
  9. 8.2.2 Johnson & Johnson Private Business Overview
  10. 8.2.3 Johnson & Johnson Private Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Private Gastrointestinal Cancer Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Private Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Gastrointestinal Cancer Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Roche Gastrointestinal Cancer Drugs Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Eli Lilly and Company
  26. 8.5.1 Eli Lilly and Company Company Information
  27. 8.5.2 Eli Lilly and Company Business Overview
  28. 8.5.3 Eli Lilly and Company Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly and Company Gastrointestinal Cancer Drugs Product Portfolio
  30. 8.5.5 Eli Lilly and Company Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Gastrointestinal Cancer Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Gastrointestinal Cancer Drugs Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Bristol-Myers Squibb Company
  44. 8.8.1 Bristol-Myers Squibb Company Company Information
  45. 8.8.2 Bristol-Myers Squibb Company Business Overview
  46. 8.8.3 Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bristol-Myers Squibb Company Gastrointestinal Cancer Drugs Product Portfolio
  48. 8.8.5 Bristol-Myers Squibb Company Recent Developments
  49. 8.9 Celgene Corporation
  50. 8.9.1 Celgene Corporation Company Information
  51. 8.9.2 Celgene Corporation Business Overview
  52. 8.9.3 Celgene Corporation Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Celgene Corporation Gastrointestinal Cancer Drugs Product Portfolio
  54. 8.9.5 Celgene Corporation Recent Developments
  55. 8.10 Amgen & Amgen Ireland
  56. 8.10.1 Amgen & Amgen Ireland Company Information
  57. 8.10.2 Amgen & Amgen Ireland Business Overview
  58. 8.10.3 Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Amgen & Amgen Ireland Gastrointestinal Cancer Drugs Product Portfolio
  60. 8.10.5 Amgen & Amgen Ireland Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gastrointestinal Cancer Drugs Value Chain Analysis
  2. 9.1.1 Gastrointestinal Cancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gastrointestinal Cancer Drugs Sales Mode & Process
  6. 9.2 Gastrointestinal Cancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gastrointestinal Cancer Drugs Distributors
  9. 9.2.3 Gastrointestinal Cancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst